(Q37588305)

21 August 2017

1 reference

title

Drug interactions in oncology: how common are they? (English)

1 reference

21 August 2017

R P Riechelmann

1

1 reference

21 August 2017

A Del Giglio

series ordinal

2

1 reference

21 August 2017

publication date

27 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

20

1 reference

21 August 2017

issue

12

1 reference

21 August 2017

page(s)

1907-1912

1 reference

Drug interactions in cancer therapy

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Prospective evaluation of adverse drug interactions in the emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Potential drug interactions and duplicate prescriptions among cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Fatal adverse drug events: the paradox of drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Potential drug interactions in cancer patients receiving supportive care exclusively.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

An adverse interaction between warfarin and capecitabine: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

A study of the interaction of omeprazole and warfarin in anticoagulated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Paracetamol: a haemorrhagic risk factor in patients on warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Proton pump inhibitors and their drug interactions: an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Interaction between paclitaxel and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

Symptom and medication profiles among cancer patients attending a palliative care clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDP369

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDP369

1 reference

21 August 2017

1 reference